Healthcare >> CEO Interviews >> July 8, 2002
JAY MOHR joined VARIAGENICS, Inc. in October 2001 serving as Vice
President, Business Development and Marketing. He was recently promoted
and now serves as President and Chief Business Officer. Prior to joining
Variagenics, Mr. Mohr was Executive Vice President of Serono, Inc.'s
Metabolic Endocrinology Strategic Business Unit where he headed North
American commercial operations for the recombinant human growth hormone
franchise (SEROSTIM' and SAIZEN'). Under Mr. Mohr's leadership,
cumulative sales for the franchise doubled. During his tenure in this
position, he led an integrated team, including sales and marketing
professionals and dedicated reimbursement and Phase IV research
functions. While at Serono, Mr. Mohr also held various senior management
positions in the company's Metabolic and Immune Therapy and MS Strategic
Business Units. Before joining Serono he was with Schering-Plough, Price
Waterhouse (now PricewaterhouseCoopers LLP), Marketing Corp. of America
and HBO & Company, serving in various management capacities. Mr. Mohr
holds an MBA from the Wharton School and a BA in Economics and German
from Vanderbilt University. Profile
leverage its core strengths and partners' needs?
Mr. Mohr: VARIANGENICS is in the business of creating novel high
